Biohaven Q1 net loss $179.5M ($2.20/shr) vs $70.5M loss a year ago; cash $287.6M plus $247.8M from April offering

Biohaven Ltd.

2024-Q1 EPS reported -$2.20

Net loss $179.5M ($2.20/shr); non-GAAP adjusted net loss $144.6M ($1.77/shr); both more than doubled vs Q1 2023.
R&D expense $156.0M, up 146% YoY, driven by advancing trials and $16.6M in shares for Pyramid Biosciences acquisition.
Cash, equivalents and marketable securities $287.6M at March 31; additional $247.8M from April 2024 public offering of 6.45M shares at $41.
FDA granted rare pediatric disease designation for taldefgrobep alfa in SMA; Phase 3 data expected 2H 2024.
Phase 2/3 programs initiated with Kv7 activator BHV-7000 in epilepsy, MDD, and bipolar; BHV-1300 MoDE shows IgG reduction.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Biohaven Ltd. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a review of recent accomplishments and anticipated upcoming developments.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Biohaven Ltd. filing history →

Source: SEC EDGAR

accession 0001935979-24-000047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.